terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 27, 2026

Clinical Data Management System Market Report 2026: Trends, Strategies and Investments | Astute Analytica

View original at finance.yahoo.com
Clinical Data Management System Market Report 2026: Trends, Strategies and Investments | Astute Analytica AstuteAnalytica India Pvt. Ltd…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The average downtime for cloud-based systems is less than 4 hours annually

    80% confidence
  • More than 70% of clinical research organizations have reported enhanced efficiency after migrating to cloud-based systems

    80% confidence
  • The global cloud computing market is estimated to rise at a 15.4% CAGR

    80% confidence
  • Cloud solutions decrease functional costs by 30% compared to on-premise systems

    80% confidence
  • Cloud solutions allow real-time data sharing across global teams, decreasing the time needed for data analysis by 40%

    80% confidence
  • The global clinical data management system market was valued at 4.08 billion in 2024 and is expected to reach US$ 10.35 billion by 2033, growing at a CAGR of 10.9% from 2025 to 2033

    80% confidence
  • The integration of blockchain technology in cloud platforms has improved data integrity, decreasing errors by 20%

    80% confidence
  • CDMS helps decrease clinical trial costs by 25% via optimized data handling

    80% confidence
  • The adoption of AI and machine learning in cloud platforms has enhanced data accuracy by 25%

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Clinical Data Management System Market Report 2026: Trends, Strategies and Investments | Astute Analytica — Source | Via News | pt.VIA.NEWS